OostNL

AMT Medical B.V., founded in 2015 and based in Ede, the Netherlands, specializes in developing innovative devices for heart bypass surgery. The company has created the AMT Heart Bypass System, which utilizes the ELANA bypass technique, originally developed by neurosurgeon Prof. Dr. C.A.F. Tulleken and his team. This minimal invasive approach aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, ultimately improving patient outcomes and recovery times. The AMT Heart Bypass System has completed its development and production processes, as well as all pre-clinical trials. A clinical multi-center trial is set to begin in late 2019 or early 2020, marking a significant step in bringing this advanced technology to the medical community.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Prolira BV is a Dutch company based in Utrecht that specializes in developing medical technology for the early detection of delirium, an acute brain failure condition. Founded in 2015, Prolira has introduced DeltaScan, an EEG-based device designed to monitor brain activity and facilitate timely treatment for patients at risk of acute encephalopathy and delirium. The DeltaScan system comprises a single-use electrode patch, known as the DeltaScan Patch, and the DeltaScan Monitor, which employs a validated proprietary algorithm to analyze EEG data. This innovative approach aims to enhance patient recovery by supporting clinicians in identifying and addressing delirium, a condition that affects approximately 20 million patients annually in hospitals across Europe and the United States, leading to significant cognitive impairment and increased healthcare costs.

ATRO Medical B.V., based in Nijmegen, the Netherlands, focuses on developing innovative solutions for knee joint health through its anatomically shaped meniscus implant, the Trammpolin. This implant is designed to restore the protective function of the meniscus by acting as a joint spacer, thus alleviating pain and improving life quality for patients suffering from osteoarthritis. The company emerged as a spin-out from DSM and Radboudumc, leveraging insights gained from a collaborative initiative that began in 2010, involving various universities and private enterprises with support from the Dutch government. The Trammpolin prosthesis is a synthetic, non-resorbable substitute that mimics the natural meniscus, functioning effectively as a shock absorber by ensuring adequate load distribution within the knee joint.

ScreenPoint Medical B.V. is a company based in Nijmegen, the Netherlands, specializing in the development of artificial intelligence software designed to assist radiologists in interpreting digital breast tomosynthesis (DBT) and mammography exams. Founded in 2014, ScreenPoint focuses on creating deep learning and image analysis technologies that enhance the accuracy and consistency of breast cancer detection. By leveraging advanced machine learning techniques alongside extensive, well-curated digital image databases, the company aims to improve the diagnostic process for breast cancer, thereby enabling earlier detection and reducing unnecessary patient recalls. Their flagship product, Transpara, exemplifies this commitment to enhancing clinical outcomes in mammography through innovative technology.

InteRNA Technologies B.V. is a biotechnology company focused on the development of microRNA (miRNA)-based therapeutics for cancer treatment. The company's innovative approach leverages the unique properties of miRNAs to target previously undruggable pathways involved in cancer initiation, progression, and metastasis. By utilizing advanced techniques such as massively parallel sequencing and proprietary bioinformatics, InteRNA analyzes and validates miRNA sequences to enhance drug efficacy and reduce resistance to existing therapies. Founded in 2006, the company operates from Nijmegen, the Netherlands, and has a dedicated research and development center in Utrecht. Recently, InteRNA has secured additional equity financing to advance its lead program for melanoma treatment, demonstrating its commitment to developing novel solutions in oncology.

Eurekite BV, based in Enschede, the Netherlands, specializes in the manufacture of flexible ceramic materials. Established in May 2015 as a spin-off from the University of Twente, the company focuses on the development and commercialization of its innovative technology, known as Flexiramics®. This technology emerged from the Inorganic Materials Science Group of the MESA + Institute for Nanotechnology, led by Professor Andre ten Elshof. Eurekite combines expertise in formulation chemistry, production technology, and composite development, with its disruptive materials attracting investment from prominent venture capital firms.

Pepscope BV, established in 2012 and headquartered in Nijmegen, the Netherlands, is a biotechnology company specializing in protein kinase activity profiling technologies. It offers QuantaKinome, a solution designed to enhance the discovery and development of novel kinase inhibitors and therapeutic compounds within the pharmaceutical industry and academic research. The company's core services include protein-kinase profiling assays and advanced proteomics services, enabling clients to achieve reproducible results and robust conclusions.

Prolira BV is a Dutch company based in Utrecht that specializes in developing medical technology for the early detection of delirium, an acute brain failure condition. Founded in 2015, Prolira has introduced DeltaScan, an EEG-based device designed to monitor brain activity and facilitate timely treatment for patients at risk of acute encephalopathy and delirium. The DeltaScan system comprises a single-use electrode patch, known as the DeltaScan Patch, and the DeltaScan Monitor, which employs a validated proprietary algorithm to analyze EEG data. This innovative approach aims to enhance patient recovery by supporting clinicians in identifying and addressing delirium, a condition that affects approximately 20 million patients annually in hospitals across Europe and the United States, leading to significant cognitive impairment and increased healthcare costs.

Plasmacure is a Netherlands-based company that specializes in developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. Their patented solution effectively kills bacteria, stimulates cell proliferation, and enhances microcirculation, which helps reduce the risk of amputation. By addressing these critical aspects of wound healing, Plasmacure's technology aims to improve the quality of life for patients suffering from chronic wounds.

SuperBuddy is a Netherlands-based delivery service that specializes in on-demand grocery shopping. The platform acts as an online marketplace, allowing users to conveniently order groceries from local stores. SuperBuddy connects customers with personal shoppers who can accommodate specific requests, ensuring that the desired items are selected. Deliveries are made within a two-hour timeframe, providing users with a quick and efficient way to receive their groceries at home.